Related Experiment Video
Updated: Jun 26, 2025

Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Slovenian Memory Clinic Organization with the Introduction of Potential New Alzheimer's Disease Treatment
Eva Zupanic1,2, Andreja Emersic1,3, Anders Wimo4,5
1Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Abstract:
Slovenia, situated in Central Europe with a population of 2.1 million, has an estimated 44,278 individuals with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia, rendering them potential candidates for disease-modifying treatment (DMT), such as lecanemab. We identified 114 potential candidates whose real-life expenses for diagnostic process surmount to more than €80,000. Treating all potential candidates nationwide would amount to €1.06 billion, surpassing Slovenia's entire annual medication expenditure for 2022 (€743 million). The introduction of DMTs and the associated logistics, along with potential complications, will significantly change societal, professional, and patient approach to treatment of Alzheimer's disease.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Dementia
The progression of dementia is generally gradual....
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

